Published in Eur J Haematol on December 20, 2010
Hyperthermia stimulates HIV-1 replication. PLoS Pathog (2012) 1.04
Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib. Blood Cancer J (2012) 0.95
Inhibition of heat shock protein (molecular weight 90 kDa) attenuates proinflammatory cytokines and prevents lipopolysaccharide-induced liver injury in mice. Hepatology (2012) 0.91
Recent advances in antimultiple myeloma drug development. Pharm Pat Anal (2014) 0.75
Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med (2012) 5.87
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood (2013) 3.78
Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (review). Int J Oncol (2012) 1.81
Increased serum levels of neutrophil gelatinase-associated lipocalin in patients with essential thrombocythemia and polycythemia vera. Leuk Lymphoma (2010) 1.46
The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: a retrospective multicentric GIMEMA experience. Am J Hematol (2011) 1.27
Clinical and laboratory features of 103 patients from 42 Italian families with inherited thrombocytopenia derived from the monoallelic Ala156Val mutation of GPIbα (Bolzano mutation). Haematologica (2011) 1.02
High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications. Br J Haematol (2014) 1.00
Concentration of circulating endothelial progenitor cells (EPC) in normal pregnancy and in pregnant women with diabetes and hypertension. Am J Obstet Gynecol (2007) 0.98
A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy. Br J Haematol (2013) 0.97
Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: A comparison of cellular, cytogenetic, molecular, and clinical features. Clin Cancer Res (2013) 0.92
Differential levels of soluble endoglin (CD105) in myeloid malignancies. J Cell Physiol (2003) 0.91
Hemoglobin level threshold for cardiac remodeling and quality of life in myelodysplastic syndrome. Leuk Res (2005) 0.90
Relevance of stereotyped B-cell receptors in the context of the molecular, cytogenetic and clinical features of chronic lymphocytic leukemia. PLoS One (2011) 0.87
Levels of soluble angiogenin in chronic myeloid malignancies: clinical implications. Eur J Haematol (2004) 0.87
The cancer stem cell hypothesis: a guide to potential molecular targets. Cancer Invest (2014) 0.86
Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study. Drugs Aging (2013) 0.86
Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study. Am J Hematol (2014) 0.85
Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma. Eur J Haematol (2013) 0.85
JAK2 V617F-positive latent essential thrombocythemia and splanchnic vein thrombosis: the role of bone marrow biopsy for the diagnosis of myeloproliferative disease. Acta Haematol (2009) 0.84
Endothelial progenitor cells: pathogenetic role and therapeutic perspectives. J Nephrol (2009) 0.84
Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia. Am J Hematol (2012) 0.84
More concern about transfusion requirement when evaluating quality of life in anemic patients. J Clin Oncol (2002) 0.83
MiRNome expression is deregulated in the peripheral lymphoid compartment of multiple myeloma. Br J Haematol (2014) 0.83
Imatinib mesylate therapy induces reduction in neutrophil gelatinase-associated lipocalin serum levels and increase in leptin concentrations in chronic myeloid leukemia patients in molecular remission. Acta Haematol (2011) 0.83
Oxidative stress in oncohematologic diseases: an update. Expert Rev Hematol (2013) 0.82
Bisphosphonates induce apoptosis of circulating endothelial cells in multiple myeloma patients and in subjects with bisphosphonate-induced osteonecrosis of the jaws. Acta Haematol (2010) 0.82
Reduced serum levels of Interleukin 17 in patients with osteonecrosis of the jaw and in multiple myeloma subjects after bisphosphonates administration. Cytokine (2008) 0.81
Epigenetic therapy in myelodysplastic syndromes. Eur J Haematol (2010) 0.80
Decreased plasma levels of IL-33 could contribute to the altered function of Th2 lymphocytes in patients with polycythemia vera and essential thrombocythemia. Cancer Invest (2013) 0.80
Reduced IL-33 plasma levels in multiple myeloma patients are associated with more advanced stage of disease. Br J Haematol (2012) 0.80
Familial B-cell chronic lymphocytic leukemia in a population of patients from Southern Italy. Int J Hematol (2004) 0.79
Immunomodulatory drugs: new options for the treatment of myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk (2012) 0.79
Increase of novel biomarkers for oxidative stress in patients with plasma cell disorders and in multiple myeloma patients with bone lesions. Inflamm Res (2012) 0.79
Effect of inner myometrium fibroid on reproductive outcome after IVF. Reprod Biomed Online (2005) 0.79
Absence of the V617F JAK2 mutation in the lymphoid compartment in a patient with essential thrombocythemia and B-chronic lymphocytic leukemia and in two relatives with lymphoproliferative disorders. Acta Haematol (2009) 0.79
Cardiac involvement in patients with hematologic malignancies. J Investig Med (2010) 0.79
Post-embryo transfer interventions for in vitro fertilization and intracytoplasmic sperm injection patients. Cochrane Database Syst Rev (2009) 0.78
Reduction in IL-33 plasma levels might be involved in T cell dysregulation in chronic lymphocytic leukemia. Acta Haematol (2013) 0.78
[Lipid profile in hematologic neoplasms]. Recenti Prog Med (2002) 0.78
Nanoparticles in oncology: the new theragnostic molecules. Anticancer Agents Med Chem (2011) 0.78
Patients with bisphosphonate-associated osteonecrosis of the jaw have unmodified levels of soluble vascular endothelial growth factor receptor 1. Leuk Lymphoma (2007) 0.78
Involvement of T2677T multidrug resistance gene polymorphism in Interleukin 22 plasma concentration in B-chronic lymphocytic leukemia patients. Acta Oncol (2011) 0.78
Severe dermatologic adverse reactions after exposure to lenalidomide in multiple myeloma patients with a positive HLA-DRB1*1501 and HLA-DQB1*0602. Acta Oncol (2011) 0.78